Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anebulo Pharmaceuticals Inc (NQ: ANEB )

1.500 -0.020 (-1.32%)
Streaming Delayed Price Updated: 3:42 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,923
Open 1.250
Bid (Size) 1.250 (1)
Ask (Size) 1.560 (1)
Prev. Close 1.520
Today's Range 1.250 - 1.680
52wk Range 1.250 - 3.300
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-39.29%
-39.29%
1 Month
-18.50%
-18.50%
3 Month
-21.96%
-21.96%
6 Month
-32.43%
-32.43%
1 Year
-28.91%
-28.91%

More News

Read More
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says
Via Benzinga
Anebulo Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Lifecore Biomedical Announces Cooperation Agreement with 22NW
From Lifecore Biomedical, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
ANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024
Via InvestorPlace
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug
Via Benzinga
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Anebulo Pharmaceuticals Announces New CEO
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Anebulo Receives Positive Feedback From FDA On Path To Phase 3 Trial Of Its Drug For Acute Cannabinoid Intoxication
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.